Large Cap Biopharmaceuticals Winners And Losers 2015-16: Which Stocks Can Outperform The ETFs In 2016?… Part 1

The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a Fed rate rise, with potentially less available equity funding, has hit all stocks.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.